Medical Principles of Intraperitoneal and Intrapleural Chemotherapy
While modeling studies have suggested a major pharmacokinetic advantage for peritoneal cavity drug exposure to certain chemotherapeutic agents when administered by the intraperitoneal route (1), there are both theoretical and practical issues which must be addressed prior to the acceptance of this approach to the management of malignant disease principally confined to the peritoneal or pleural cavities. The importance of establishing a safe and simple method of accessing the abdominal cavity has been discussed in another paper in this symposium.
KeywordsPeritoneal Dialysis Ovarian Carcinoma Pleural Fluid Pleural Cavity Body Cavity
Unable to display preview. Download preview PDF.
- 9.King ME, Howell SB: Intraperitoneal cytarabine therapy in ovarian carcinoma. J Clin Oncol (in press), 1983.Google Scholar
- 10.Alberts DS, Chen HSG, Chang SY, Peng YM: The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. Recent Results in Cancer Res 74: 293 - 299, 1980.Google Scholar
- 11.Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Green R, Jenkins J, Myers CE: Phase I and pharmacological studies of Adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer 42: 4265–4269, 1982.Google Scholar